UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
European journal of pharmaceutical sciences, ISSN 0928-0987, 02/2019, Volume 128, pp. 18 - 26
Ezetimibe glucuronide | Joint population pharmacokinetic model | Enterohepatic recirculation | Ezetimibe | Glucuronides - pharmacokinetics | Hypolipidemic Agents - metabolism | Humans | Ezetimibe - metabolism | Azetidines - metabolism | Azetidines - pharmacokinetics | Azetidines - chemistry | Ezetimibe - blood | Ezetimibe - chemistry | Glucuronides - metabolism | Models, Biological | Ezetimibe - pharmacokinetics | Drug Compounding | Adult | Hypolipidemic Agents - chemistry | Hypolipidemic Agents - pharmacokinetics | Glucuronides - chemistry | Index Medicus
Journal Article
Carbohydrate polymers, ISSN 0144-8617, 10/2015, Volume 130, pp. 26 - 31
Solid dispersion | Bioavailability | Tween 80 | Ezetimibe | Solubility | Hydroxypropylcellulose | Physical Sciences | Chemistry | Chemistry, Organic | Polymer Science | Chemistry, Applied | Science & Technology | Polysorbates - chemistry | Administration, Oral | Biological Availability | Male | Ezetimibe - administration & dosage | Rats, Sprague-Dawley | Drug Carriers - chemistry | Cellulose - chemistry | Animals | Ezetimibe - chemistry | Ezetimibe - pharmacokinetics | Surface-Active Agents - chemistry | Cellulose - analogs & derivatives | Surface active agents | Pharmacy | Antilipemic agents | Index Medicus
Journal Article
European heart journal, ISSN 0195-668X, 05/2015, Volume 36, Issue 19, pp. 1186 - 1194
Alirocumab | Monoclonal antibody | Low-Density Lipoprotein Cholesterol | Ezetimibe | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Double-Blind Method | Drug Administration Schedule | Ezetimibe - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Ezetimibe - administration & dosage | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Injections, Subcutaneous | Cholesterol, LDL - metabolism | Female | Index Medicus | Track Clinical Paper
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system | Medicin och hälsovetenskap
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1580 - 1590
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myalgia - blood | Myalgia - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Myositis - chemically induced | Hypercholesterolemia - drug therapy | Myositis - prevention & control | Time Factors | Adult | Cholesterol, LDL - blood | Female | Muscular Diseases - prevention & control | Ezetimibe - therapeutic use | Muscular Diseases - chemically induced | Atorvastatin Calcium - adverse effects | Hypercholesterolemia - blood | Myalgia - prevention & control | Creatine Kinase - blood | Double-Blind Method | Ezetimibe - adverse effects | Biomarkers - blood | Myositis - blood | Anticholesteremic Agents - adverse effects | Muscular Diseases - blood | Rhabdomyolysis - prevention & control | Cross-Over Studies | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Rhabdomyolysis - chemically induced | Rhabdomyolysis - blood | Side effects | Muscular system | Comparative analysis | Drug therapy | Low density lipoprotein | Statins
Journal Article
European heart journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 32, pp. 2459 - 2472
Journal Article
Current medicinal chemistry, ISSN 0929-8673, 03/2016, Volume 23, Issue 10, pp. 983 - 999
Cardiovascular disease | Cholesterol absorption | LDL-C | NPC1L1 | Cholesterol | Ezetimibe | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Ezetimibe - chemistry | Cardiovascular Diseases - metabolism | Membrane Proteins - antagonists & inhibitors | Simvastatin - chemistry | Cardiovascular Diseases - drug therapy | Humans | Ezetimibe - pharmacology | Simvastatin - pharmacology | Ezetimibe - chemical synthesis
Journal Article
Atherosclerosis, ISSN 0021-9150, 2015, Volume 244, pp. 138 - 146
Cardiovascular | PCSK9 | Rosuvastatin | Alirocumab | Monoclonal antibody | Low-density lipoprotein cholesterol | Ezetimibe | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypercholesterolemia - blood | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Cholesterol, LDL - drug effects | Treatment Outcome | Ezetimibe - administration & dosage | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Dose-Response Relationship, Drug | Time Factors | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - blood | Cholesterol, LDL - blood | Retrospective Studies | Drug Therapy, Combination | Cardiac patients | Index Medicus
Journal Article
European journal of pharmaceutical sciences, ISSN 0928-0987, 01/2016, Volume 82, pp. 21 - 30
Atorvastatin | Solid dispersion | In vivo evaluation | Ezetimibe | Liver steatosis | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Liver - pathology | Hyperlipidemias - blood | Rats, Wistar | Atorvastatin Calcium - pharmacology | Fatty Liver - blood | Fatty Liver - pathology | Atorvastatin Calcium - administration & dosage | Cholesterol - blood | Hyperlipidemias - drug therapy | Atorvastatin Calcium - chemistry | Ezetimibe - pharmacology | Solubility | Male | Ezetimibe - administration & dosage | Fatty Liver - drug therapy | Povidone - chemistry | Animals | Ezetimibe - chemistry | Liver - drug effects | Diet, High-Fat | Hyperlipidemias - pathology | Ezetimibe - therapeutic use | Atorvastatin Calcium - therapeutic use | Drug Combinations | Low density lipoproteins | Analysis | Liver | Antilipemic agents | Index Medicus
Journal Article
European heart journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 32, pp. 2459 - 2472
METAANALYSIS | Ezetimibe | Clinical trials | Cardiovascular disease | PCSK9 | RISK | Mendelian randomization | Statin | Low-density lipoprotein | Recommendations | LDL CHOLESTEROL | TRIAL | GENERAL-POPULATION | STATIN THERAPY | HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | CHOLESTEROL-FED RABBITS | Atherosclerosis | Causality | CORONARY-HEART-DISEASE | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Genetic Predisposition to Disease - genetics | Cholesterol, HDL - metabolism | Lipoproteins, LDL - physiology | Hyperlipidemias - prevention & control | Consensus | Atherosclerosis - etiology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Epidemiologic Methods | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, LDL - metabolism | Ezetimibe - therapeutic use | Atherosclerosis - prevention & control | Index Medicus | Current Opinion | Kardiologi | Cardiac and Cardiovascular Systems
Journal Article